Dabigatran Inhibitors
1 drugsAbout Dabigatran
Dabigatran is a clinically important drug target involved in anticoagulation by modulating the coagulation cascade, a series of events leading to blood clot formation. Targeting Dabigatran is crucial for preventing and treating thromboembolic disorders.
Currently, there is no genetic evidence directly linking Dabigatran to specific diseases. However, the clinical utility of the antibody drug PRAXBIND highlights the importance of this target in managing conditions where excessive blood clotting poses a risk.
Dabigatran is targeted by one FDA-approved antibody drug, PRAXBIND (Boehringer Ingelheim), used in therapeutic areas classified as 'other'. Boehringer Ingelheim is the only company with an approved drug targeting Dabigatran.
Top Dabigatran Drugs
Boehringer Ingelheim is the only company with an approved drug targeting Dabigatran.
The lack of competition suggests a high barrier to entry or an underserved market.
Dabigatran Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Dabigatran, using antibody modality.
Exploring alternative modalities like small molecules could provide a competitive advantage.
Dabigatran Clinical Trials 6 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Dabigatran. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 3 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Dabigatran Drug Approval Timeline (2015 - 2015)
The first and most recent drug approval for Dabigatran was PRAXBIND in 2015.
The single approval in 2015 indicates a potentially saturated market or limited innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Dabigatran. A trial counts if an approved drug acting on Dabigatran is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.